Skip to main content
. 2018 Apr 13;7(8):e007987. doi: 10.1161/JAHA.117.007987

Figure 2.

Figure 2

Associations between combined (new and baseline) mineralocorticoid antagonist (MRA) use and outcomes in unadjusted (blue, top line) and propensity‐matched (orange, bottom line) patients. Ratios <1 (to the left) favor patients on MRA therapy. Ratios >1 (to the right) favor patients never on MRA therapy. *Odds ratios are reported, with others as hazard ratios. AF indicates atrial fibrillation; CV, cardiovascular; TIA, transient ischemic attack.